Abivax SA Sponsored ADR $ABVX Holdings Decreased by BVF Inc. IL

BVF Inc. IL decreased its holdings in shares of Abivax SA Sponsored ADR (NASDAQ:ABVX) by 9.0% during the fourth quarter, HoldingsChannel.com reports. The institutional investor owned 508,031 shares of the company’s stock after selling 50,000 shares during the quarter. Abivax makes up 2.3% of BVF Inc. IL’s investment portfolio, making the stock its 14th largest position. BVF Inc. IL’s holdings in Abivax were worth $68,511,000 as of its most recent filing with the Securities and Exchange Commission.

A number of other institutional investors and hedge funds have also modified their holdings of the business. ACT Capital Management LLC purchased a new position in shares of Abivax during the fourth quarter valued at $8,617,000. Guggenheim Capital LLC grew its holdings in shares of Abivax by 45.4% during the fourth quarter. Guggenheim Capital LLC now owns 25,086 shares of the company’s stock valued at $3,383,000 after buying an additional 7,828 shares in the last quarter. Schonfeld Strategic Advisors LLC grew its holdings in shares of Abivax by 29.2% during the fourth quarter. Schonfeld Strategic Advisors LLC now owns 9,379 shares of the company’s stock valued at $1,265,000 after buying an additional 2,119 shares in the last quarter. Cetera Investment Advisers purchased a new position in shares of Abivax during the fourth quarter valued at $905,000. Finally, Ally Bridge Group NY LLC purchased a new position in shares of Abivax during the fourth quarter valued at $9,440,000. Hedge funds and other institutional investors own 47.91% of the company’s stock.

Wall Street Analyst Weigh In

ABVX has been the topic of a number of research analyst reports. Weiss Ratings reiterated a “sell (d-)” rating on shares of Abivax in a report on Monday, April 20th. Wolfe Research set a $136.00 target price on Abivax in a research note on Wednesday, June 3rd. Wall Street Zen upgraded Abivax from a “sell” rating to a “hold” rating in a research note on Saturday, May 23rd. Citizens Jmp boosted their target price on Abivax from $131.00 to $187.00 and gave the company a “market outperform” rating in a research note on Tuesday, June 2nd. Finally, Wedbush upgraded Abivax from an “underperform” rating to a “neutral” rating and lowered their target price for the company from $110.00 to $90.00 in a research note on Tuesday, June 2nd. Twelve equities research analysts have rated the stock with a Buy rating, two have issued a Hold rating and one has assigned a Sell rating to the company’s stock. According to MarketBeat, the stock currently has an average rating of “Moderate Buy” and a consensus target price of $130.08.

Abivax Price Performance

Shares of NASDAQ ABVX opened at $100.15 on Thursday. The company has a market capitalization of $7.99 billion, a P/E ratio of -19.22 and a beta of 0.69. The business’s 50-day moving average price is $114.81 and its two-hundred day moving average price is $118.49. Abivax SA Sponsored ADR has a one year low of $5.69 and a one year high of $148.83.

Abivax (NASDAQ:ABVX) last released its quarterly earnings results on Friday, May 22nd. The company reported ($0.71) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.94) by $0.23. The company had revenue of $1.56 million for the quarter, compared to the consensus estimate of $0.40 million. On average, equities analysts anticipate that Abivax SA Sponsored ADR will post -3.4 EPS for the current year.

About Abivax

Founded in 2013 and headquartered in Paris, France, Abivax is a clinical-stage biopharmaceutical company focused on discovering and developing novel therapies for chronic inflammatory diseases and viral infections. The company’s technology platform targets host RNA biogenesis to modulate key immune pathways, offering a differentiated approach aimed at disease modification and improved safety profiles.

Abivax’s lead clinical asset, obefazimod (ABX464), is being evaluated in ulcerative colitis and other inflammatory disorders.